BlackRock Amends Celldex Therapeutics Stake, Holds Significant Position
Ticker: CLDX · Form: SC 13G/A · Filed: Jan 26, 2024 · CIK: 744218
| Field | Detail |
|---|---|
| Company | Celldex Therapeutics, Inc. (CLDX) |
| Form Type | SC 13G/A |
| Filed Date | Jan 26, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investing
TL;DR
**BlackRock still owns a big chunk of Celldex, signaling institutional confidence.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 26, 2024, disclosing its ownership in Celldex Therapeutics, Inc. (CDLX) as of December 31, 2023. This filing indicates that BlackRock, a major institutional investor, continues to hold a significant stake in Celldex, which could be seen as a vote of confidence in the company's future prospects. For investors, this matters because large institutional holdings can provide stability and signal that professional money managers see value in the stock.
Why It Matters
This filing shows that a major institutional investor, BlackRock, maintains a substantial interest in Celldex Therapeutics, which can influence market perception and potentially provide a floor for the stock price.
Risk Assessment
Risk Level: low — This filing is a routine update from a large institutional investor and does not indicate any immediate negative risks for Celldex Therapeutics.
Analyst Insight
An investor should note that BlackRock's continued holding in Celldex Therapeutics suggests ongoing institutional interest, but this filing alone doesn't provide new information on the size or change in their stake, so further due diligence on BlackRock's specific share count would be beneficial.
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- Celldex Therapeutics, Inc. (company) — the subject company in which BlackRock holds shares
- December 31, 2023 (date) — the date of the event requiring the filing
- January 26, 2024 (date) — the filing date of the SC 13G/A
- 15117B202 (other) — the CUSIP number for Celldex Therapeutics' Common Stock
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, filed under the Securities Exchange Act of 1934.
Who is the 'Subject Company' in this filing?
The 'Subject Company' is Celldex Therapeutics, Inc., identified by CIK 0000744218.
Who is the 'Filed By' entity in this document?
The 'Filed By' entity is BlackRock Inc., identified by CIK 0001364742.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023.
What is the CUSIP Number for the securities mentioned in this filing?
The CUSIP Number for the Common Stock of Celldex Therapeutics, Inc. is 15117B202.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 26, 2024 regarding Celldex Therapeutics, Inc. (CLDX).